Opinion|Videos|January 23, 2025
Influence of DESTINY-PanTumor02 Trials on Trastuzumab Deruxtecan Usage
Author(s)Misako Nagasaka, MD, PhD
Panelist discusses how the DESTINY-PanTumor02 study enrolled 267 patients with different tumor types, including endometrial, cervical, ovarian, bladder, biliary tract, and pancreatic cancer.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do the results from the DESTINY-PanTumor02 trials influence your approach to using trastuzumab deruxtecan in HER2-expressing solid tumors?
- DESTINY-PanTumor02 (Bernstam F. J Clin Oncol. 2024)
Advertisement
Related to this article
Poster sessions at WCLC 2026 detail how surgery, nursing, and pathology can contribute to the multidisciplinary care of patients with lung cancer.
Medical oncologists, clinical pharmacists, and oncologic nurse practitioners share the presentation topics to look out for at WCLC 2026.
The interim 3-year OS rates were 71.2% with OST-HER2 vs 45.8% in historical controls in a phase 2b trial of fully resected, pulmonary metastatic osteosarcoma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Lutetium Lu 177 Dotatate Biosimilar Earns Final FDA Approval in GEP-NETs
2
Rusfertide Earns Category 1 NCCN Recommendation in Polycythemia Vera
3
PANXEON Liquid Biopsy Demonstrates Potential for Detecting Early Pancreatic Cancer
4
Distinguishing HER2 Mutations From Amplification in NSCLC Testing
5